Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR... see more

TSX:OPS - Post Discussion

Opsens Inc > Another reminder
View:
Post by Nadia6519 on Dec 02, 2022 10:25am

Another reminder

QUEBEC CITYOct. 26, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced the successful completion of the first cases in a clinical study, named SAFE-TAVI, studying SavvyWire™ left ventricular rapid pacing in transcatheter aortic valve replacement procedures, or TAVR, in Europe. Dr. Regueiro from Hospital Clnic de Barcelona, Spain, conducted the procedures as one of the primary investigators of the study. This study is part of the OpSens pre-CE mark clinical strategy that will lead to the commercialization of SavvyWire in Europe.

OPSENS Logo (CNW Group/OpSens Inc.)

OpSens' SavvyWire has previously received Health Canada and U.S. FDA clearance. Using SavvyWire for left ventricular pacing can eliminate the need for venous access, reduce procedure time, and avoid potential complications associated with right ventricular pacing.

Dr. Josep Rods-Cabau, from the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et de Pneumologie de Qubec or "IUCPQ"), is the global principal investigator of the SAFE-TAVI study that will enroll 120 patients with, among other conditions, severe aortic valve stenosis requiring a TAVR procedure in which left ventricular rapid pacing is considered necessary.

The SAFE-TAVI study is planned to be conducted at up to nine hospitals: in eight renowned centers across Spain and in Canada, at the IUCPQ. As the global principal investigator of the SAFE-TAVI study, Dr. Rods-Cabau will oversee and coordinate the principal investigators in their respective Spanish hospitals.

"I am extremely pleased with the performance of the SavvyWire," said Dr. Regueiro from Hospital Clnic de Barcelona. "We successfully used it on three cases today, implanting three different systems, including a NavitorTM TAVI System from Abbott, an Evolut system from Medtronic, and a SAPIEN 3 valve from Edwards Lifesciences. There is no doubt the SavvyWire allowed us to optimize our efficiency and workflow, while enhancing accuracy and patient safety."

Comment by 88guy88 on Dec 02, 2022 10:34am
Just chill....re posting press releases will not make the price go up....walk away from your computer and go shopping or go get a Tims and a donut....the price is beyond your control....you need to be objective with your investment
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities